Clinical Trial: A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07910942) titled 'A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer' on Oct. 27.

Brief Summary: The goal of this Phase 1 clinical trial is to learn whether KAN-001, an investigational live biotherapeutic product, can be safely given with pembrolizumab, with or without chemotherapy, to adults with PD-L1-positive, inoperable or metastatic non-small cell lung cancer. The main questions it aims to answer are:

* What side effects occur when KAN-001 is given with pembrolizumab, with or without chemotherapy?

* Can the microbial strains contained in KAN-001 be detected...